Top Page
bioAffinity Technologies, Inc.
(NASDAQ:BIAF)
bioAffinity Technologies, Inc. (BIAF) vs. SPDR S&P 500 ETF (SPY)
bioAffinity Technologies, Inc. Business Overview & Revenue Model
bioAffinity Technologies, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.78M | 9.36M | 2.53M | 4.80K | 0.00 | 0.00 |
| Gross Profit | 1.62M | 3.38M | 791.62K | 4.34K | -4.82K | -22.24K |
| EBITDA | -14.11M | -8.33M | -7.63M | -5.61M | -5.32M | -6.86M |
| Net Income | -14.74M | -9.04M | -7.94M | -8.15M | -6.33M | -7.27M |
Balance Sheet | ||||||
| Total Assets | 11.55M | 6.51M | 8.22M | 12.18M | 1.45M | 145.60K |
| Cash, Cash Equivalents and Short-Term Investments | 7.67M | 1.11M | 2.82M | 11.41M | 1.36M | 83.11K |
| Total Debt | 680.95K | 1.50M | 1.58M | 251.75K | 11.36M | 10.01M |
| Total Liabilities | 2.64M | 3.91M | 3.37M | 1.14M | 17.24M | 15.22M |
| Stockholders Equity | 8.90M | 2.60M | 4.86M | 11.04M | -15.79M | -15.07M |
Cash Flow | ||||||
| Free Cash Flow | -8.51M | -7.34M | -6.06M | -4.29M | -2.05M | -2.21M |
| Operating Cash Flow | -8.45M | -7.26M | -6.04M | -4.07M | -2.05M | -2.21M |
| Investing Cash Flow | -60.57K | -79.08K | -2.21M | -219.99K | 0.00 | -2.89K |
| Financing Cash Flow | 15.42M | 5.63M | -344.98K | 14.34M | 3.33M | 1.72M |
bioAffinity Technologies, Inc. Technical Analysis
bioAffinity Technologies, Inc. Risk Analysis
bioAffinity Technologies, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $7.52M | ― | ― | ― | ― | ― | |
39 Underperform | $6.36M | -0.07 | -296.20% | ― | -67.73% | 58.35% | |
39 Underperform | $9.40M | -0.10 | -245.18% | ― | -27.66% | 13.18% | |
37 Underperform | $6.24M | ― | -223.45% | ― | 3.26% | 65.96% | |
34 Underperform | $5.82M | -0.01 | -236.34% | ― | ― | 98.86% |
bioAffinity Technologies, Inc. Corporate Events
bioAffinity Technologies, Inc. is a biotechnology company specializing in noninvasive diagnostics for early-stage lung cancer and other lung diseases, with its flagship product being the CyPath® Lung test.
On November 5, 2025, bioAffinity Technologies announced significant growth in the volume of their CyPath® Lung tests, with October’s test volume showing a 111% increase over the 2025 monthly average. This growth reflects the increasing recognition of the test’s clinical value by physicians and the success of the company’s outreach efforts to healthcare providers. The steady adoption of CyPath® Lung is seen as a step towards changing the standard of care in early lung cancer detection.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On October 28, 2025, bioAffinity Technologies announced that the Australian Patent Office accepted its patent application for a platform technology to assess lung health and predict multiple lung diseases. This acceptance strengthens bioAffinity’s global patent portfolio, enhancing its market positioning and protecting its core technology, which is crucial for the CyPath® Lung test and other diagnostics in development.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
bioAffinity Technologies, Inc. is spearheading a clinical study titled ‘Detection of Early-Stage Lung Cancer in Sputum Using Flow Cytometry and an Automated Analysis Pipeline.’ The study aims to assess the FlowPath Lung Diagnostic Test’s ability to detect lung cancer in high-risk individuals with existing lung nodules, sized between 6 to 30 mm, as determined by low-dose computed tomography (LDCT). This study is significant as it seeks to provide a non-invasive diagnostic method for early-stage lung cancer detection, potentially improving patient outcomes.
bioAffinity Technologies, Inc. is conducting a study titled ‘Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer.’ The study aims to compare assay results to current lung cancer detection standards and optimize sputum collection methods. This research is significant as it could enhance early lung cancer detection and improve patient outcomes.
On October 20, 2025, bioAffinity Technologies announced its participation in CHEST 2025, where they will present research supporting the CyPath® Lung test’s methods for collecting and transporting patient samples. The study highlights the test’s ability to detect early-stage lung cancer with high sensitivity and specificity, potentially improving patient outcomes.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On October 16, 2025, bioAffinity Technologies, Inc. announced it received a notification of allowance from the United States Patent and Trademark Office for a patent titled ‘Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.’ This patent covers a system and method for predicting lung cancer by analyzing patient sputum samples using an AI-built algorithm and flow cytometry platform. This development enhances bioAffinity’s intellectual property portfolio, which includes 18 awarded and 33 pending patents globally, and reinforces its position in the early-stage cancer diagnostics industry. The CyPath® Lung test, integral to this patent, offers high sensitivity and specificity in detecting early-stage lung cancer, potentially improving patient outcomes and reducing healthcare costs.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On October 15, 2025, bioAffinity Technologies announced it has regained compliance with Nasdaq’s listing requirements, ensuring its common stock and warrants continue trading on the Nasdaq Capital Market. This compliance allows the company to focus on advancing its CyPath® Lung test and broader diagnostic pipeline, while a mandatory one-year panel monitor will oversee adherence to the equity rule, with potential delisting if compliance is not maintained.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On October 8, 2025, bioAffinity Technologies, Inc. announced a securities purchase agreement with institutional investors for a registered direct offering of 720,000 shares of common stock, which closed on October 9, 2025, raising approximately $1.8 million. The proceeds are intended to support working capital, growing sales for CyPath® Lung, and general corporate purposes, with WallachBeth Capital, LLC acting as the sole placement agent. The company has agreed to certain restrictions on issuing additional shares and entering variable rate transactions until specified dates, impacting their operational flexibility and market strategy.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On October 7, 2025, bioAffinity Technologies announced a significant increase in sales of its CyPath® Lung diagnostic test for lung cancer, with a 95% rise in the third quarter of 2025 compared to the previous quarter. This growth is attributed to increased adoption by Veterans’ hospitals and expansion in the mid-Atlantic region. The test’s ability to detect early-stage lung cancer and prevent unnecessary invasive procedures has boosted physician confidence and integration into clinical practice, leading to a 77% increase in new patient usage. The company’s advancements highlight its strengthening position in the diagnostic market and its positive impact on patient care.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On September 29, 2025, bioAffinity Technologies, Inc. completed a public offering of common stock and pre-funded warrants, raising approximately $4.8 million. The proceeds are intended for working capital and general corporate purposes. The company has entered into agreements restricting further issuance of shares for a certain period, aiming to stabilize its market position. Additionally, bioAffinity Technologies has been working to regain compliance with Nasdaq’s listing requirements, including implementing a reverse stock split to meet the Minimum Bid Price Requirement. The company has made significant progress in addressing these compliance issues, including increasing its stockholders’ equity and eliminating certain liabilities.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On July 25, 2025, bioAffinity Technologies, Inc. held its annual meeting where stockholders approved a reverse stock split of the company’s common stock. The board decided on a 1-for-30 reverse split, which became effective on September 18, 2025, and aimed to comply with Nasdaq’s minimum bid price requirement. This adjustment will not affect stockholders’ percentage ownership, except for those receiving cash instead of fractional shares.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On September 9, 2025, bioAffinity Technologies announced a new case study demonstrating the effectiveness of its CyPath® Lung test in identifying lung cancer in a patient with ground-glass nodules. The test shifted the patient’s care from a prolonged period of watchful waiting to immediate treatment, highlighting its potential to improve patient outcomes by providing timely, actionable information. This advancement underscores the product’s capability to reduce uncertainty in diagnosing difficult-to-assess lung nodules, positioning bioAffinity Technologies as a key player in enhancing lung cancer diagnostics.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
bioAffinity Technologies, Inc., a Delaware corporation, has prepared presentation materials for use in various presentations about the company’s operations and performance. These materials are intended for events such as the H.C. Wainwright 27th Annual Global Investment Conference scheduled from September 8, 2025, to September 10, 2025. The presentation materials, furnished as Exhibit 99.1, are part of a Current Report on Form 8-K and are not considered filed under the Securities Exchange Act of 1934. This announcement highlights the company’s efforts to engage with investors and stakeholders through strategic presentations, potentially impacting its market visibility and investor relations.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On September 3, 2025, bioAffinity Technologies announced that U.S. Medicine Magazine featured their CyPath® Lung test in its pulmonary issue, recognizing its potential to enhance lung cancer detection and reduce costs for the Department of Veterans Affairs. The test has shown high sensitivity, specificity, and accuracy in detecting early-stage lung cancer, with significant potential savings for healthcare systems by reducing unnecessary follow-up procedures. This recognition underscores the test’s value in improving patient outcomes and its economic benefits, particularly for veterans at higher risk of developing lung cancer.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On September 2, 2025, bioAffinity Technologies, Inc. announced an agreement with warrant holders to amend the Floor Price of its May and August 2025 Warrants, increasing it from $0.10 to $0.15. This amendment, effective as of August 12, 2025, resulted in a reduction of shares issuable upon exercise of the May 2025 Warrants from 53,377,497 to 35,584,997, while the August 2025 Warrants remain subject to shareholder approval.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
On August 12, 2025, bioAffinity Technologies appointed Roberto Rios and John J. Oppenheimer to its Board of Directors, enhancing the company’s financial and clinical expertise. The appointments are part of a strategic move to bolster the company’s growth and development in diagnostics for lung diseases, following Gary Rubin’s resignation from the board.
The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.